280 related articles for article (PubMed ID: 18554960)
1. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients.
Jensen SB; Mouridsen HT; Bergmann OJ; Reibel J; Brünner N; Nauntofte B
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Aug; 106(2):217-26. PubMed ID: 18554960
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
3. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
[TBL] [Abstract][Full Text] [Related]
4. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
5. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
[No Abstract] [Full Text] [Related]
6. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study.
Napeñas JJ; Brennan MT; Coleman S; Kent ML; Noll J; Frenette G; Nussbaum ML; Mougeot JL; Paster BJ; Lockhart PB; Bahrani-Mougeot FK
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr; 109(4):554-60. PubMed ID: 20303053
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction.
Jensen SB; Mouridsen HT; Reibel J; Brünner N; Nauntofte B
Oral Oncol; 2008 Feb; 44(2):162-73. PubMed ID: 17588802
[TBL] [Abstract][Full Text] [Related]
8. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
10. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
Han S; Kim J; Sohn S; Kwak GH; Kim JY; Park K
J Surg Oncol; 2007 Jan; 95(1):45-50. PubMed ID: 17192866
[TBL] [Abstract][Full Text] [Related]
12. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
[TBL] [Abstract][Full Text] [Related]
13. [Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].
Sauer R; Martus P
Strahlenther Onkol; 1996 Sep; 172(9):516-7. PubMed ID: 8928060
[No Abstract] [Full Text] [Related]
14. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
[TBL] [Abstract][Full Text] [Related]
15. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
[TBL] [Abstract][Full Text] [Related]
16. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
[TBL] [Abstract][Full Text] [Related]
17. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
[TBL] [Abstract][Full Text] [Related]
18. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Cold S; Edlund P; Ewertz M; Jensen BB; Kamby C; Nordenskjold B; Bergh J
Eur J Cancer; 2007 Mar; 43(5):877-84. PubMed ID: 17306974
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
